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 Introduction 
 Antipsychotic use is a common treatment for patients with 
schizophrenia and bipolar disorder. With the advent of the 
atypical antipsychotics (AAPs), the rates of undesirable metabolic 
complications like weight gain and type II diabetes mellitus has 
increased within these patient populations. 1 In addition, lifestyle 
habits and pharmacogenetics have been touted as having a 
role in developing type II diabetes within these populations. 2,3 
Although several pharmacogenetic variants have been implicated 
in the metabolic dysregulations seen with AAP use, 4,5 one that is 
currently emerging within the general population is the brain-
derived neurotrophic factor (BDNF). 6,7 Th e BDNF Val66Met 
(196 G/A) variant has been implicated in both schizophrenia and 
bipolar disorder due to its role in neuronal health, development, 
and function. 8,9 
 Pharmacogenetically, a BDNF gene variant identifi ed at 
codon 66 results in a methionine (Met) substitution for valine 
(Val) and results in a drastic impairment of BDNF packaging and 
distribution. 10 In animal and human models within the general 
population, the Met allele is associated with an increased risk 
of diabetes and insulin resistance through altered regulation 
of glucose metabolism and feeding habits. 11 Given the strong 
relationship between mental illness, AAP treatment, and glucose 
regulation, BDNF genetic variability may mediate development 
of type 2 diabetes (T2DM) in a large percentage of AAP treated 
patients. However, the relationship between this variant and 
glucose dysregulation seen in schizophrenia and bipolar disorder 
has not been studied. Although all metabolic complications 
carry a certain degree of risk, development of T2DM adds 
additional risks. Th erefore, these patients require careful clinical 
monitoring. 
 It is standard of practice to treat cholesterol abnormalities 
with hydroxymethylglutaryl CoA reductase inhibitors also known 
as “statins.” Th ese medications have recently been implicated in 
increasing the risk of diabetes and insulin resistance 12 and also 
have eff ects on circulating BDNF and the cleavage of pro-BDNF 
in certain populations. 13,14 Th eir cautious use in populations 
at increased risk for diabetes like that of schizophrenia and 
bipolar disorder has been advised, however, work delineating 
the true extent of this risk in those with a serious mental illness 
is unknown. 
 This investigation sought to determine the relationship 
between the BDNF 66 Met allele and insulin resistance in 
schizophrenia and bipolar patients. In addition, we determined 
the relationship between statin medication use, BDNF 66Met 
allele carriers and insulin resistance in this same cohort. 
 Materials and Methods 
 Subjects and data collection 
 Participants were recruited from Southeastern Michigan mental 
health clinics using the following study inclusion criteria: (i) 
Diagnostic and Statistical Manual of Mental Disorders Fourth 
Edition (DSM-IV) diagnosis of schizophrenia, schizophreniform 
disorder, schizoaff ective disorder, or bipolar disorder, (ii) 18–90 years 
old, and (iii) no medication changes in the prior 6 months. 
Participants were excluded if they were unable to give informed 
consent, had diabetes before starting antipsychotic treatment, had 
any condition signifi cantly aff ecting glucose and insulin measures or 
had an active substance abuse diagnosis. Th e protocol was approved 
by the University of Michigan Institutional Review Boards. 
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 Abstract 
 Introduction:  The brain-derived neurotrophic factor (BDNF) Val66Met variant and HMG-COA reductase inhibitors (statins) have been 
implicated in insulin resistance with a possible increased risk of diabetes. We sought to determine the effect of the BDNF Met variant 
and statin medication use on insulin resistance in schizophrenia and bipolar disorder using the homeostasis model assessment of 
insulin resistance (HOMA-IR). 
 Methods:  A cross-sectional design was used and patients with diabetes or on any medications affecting glucose regulation were 
 excluded. Associations between insulin resistance and genotype were then analyzed by ANOVA and regression analysis. Subjects were 
grouped by BDNF genotype as well as presence of statin. 
 Results:  Two hundred fi fty-two subjects with a mean age of 44 years were included. The group was 53% male and 41% had a diagnosis 
of bipolar disorder; 78% and 19% were receiving atypical antipsychotics (AAPs) and statin medications, respectively. Analysis showed 
schizophrenia subjects with the BDNF met allele as well as schizophrenia subjects with both the BDNF met allele and were receiving 
a statin had signifi cantly higher HOMA-IR values compared to the other groups ( p = 0.046 and  p = 0.016, respectively). 
 Conclusions:  Our results suggest that in the metabolically high-risk population of schizophrenia the BDNF met allele alone and in 
combination with statin medications is associated with higher insulin resistance values. This was not seen in the bipolar population. 
Further validation of these associations remains necessary. Clin Trans Sci 2012; Volume 5: 486–490 
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 Study visits took place within 2 hours of the subject’s 
usual wakening time, with most visits being completed by 11 
am. Height, weight, and waist circumference were measured 
in all participants. Fasting plasma glucose, triglycerides, total 
cholesterol, high-density lipoprotein and low-density lipoprotein 
measures were obtained, and the homeostasis model assessment 
of insulin resistance (HOMA-IR) 15 was calculated for each patient 
using the following formula: 
 HOMA-IR =  [fasting insulin (pIU/mL) × fasting 
blood glucose (mmol/L)]/22.5 
 Although various thresholds for insulin resistance have been 
identifi ed, 16 a HOMA-IR above 2.6 was used as a threshold for 
insulin resistance. 17 
 Subjects were excluded from this analysis if they had a 
documented diabetes diagnosis or were receiving diabetes 
treatment since treatment for diabetes would artifi cially lower 
insulin resistance values giving a false negative fi nding using the 
HOMA-IR. 
 Each patient was assessed for metabolic syndrome using the 
National Cholesterol Education Program Adult Treatment Panel III 
(NCEP ATP-III Criteria). 18 Structured Clinical Interview for DSM 
Diagnoses (SCID) conducted by a trained research assistant and 
medical record review was used to confi rm diagnoses. Participant 
complete medication histories were collected by medical record 
and patient interview. Social histories were also completed. 
Subjects were segregated to account for metabolic side eff ects 
diff erences for a given antipsychotic as follows: (1) olanzapine or 
clozapine, (2) quetiapine, risperidone, paliperidone or iloperidone, 
and (3) all other antipsychotics or no antipsychotic. 
 Analytical methods 
 DNA was extracted from whole blood 19 and for genotyped for the 
BDNF Val66Met variant (DBSNP rs6265) using Pyrosequencing. 20 
Pyrosequencing primers were designed using Pyrosequencing 
Nucleotide Polymorphism (SNP) primer design version 1.01 
soft ware ( http://www.pyrosequencing.com ). Conditions for the 
specifi c assay are available upon request. 
 Statistical analysis 
 Due to the anticipated low-genotype frequency of the BDNF 
66MetMet genotype, the statistical analysis was performed by 
forming two groups: ValVal genotype and those carrying a Met 
allele (ValMet or MetMet genotypes). For our second aim, the 
genotype groups were stratifi ed by presence or absence of statin 
use. Th e primary group of interest within this second aim was 
those subjects taking statins and carrying a 66 Met Allele compared 
to all others. A power analysis showed that to detect a clinically 
meaningful diff erence of 1.0 in HOMA-IR with a power of 80% a 
sample size approximately 56 was needed. Student  t -tests and chi-
square analyses were used for baseline demographics comparisons 
based on the two genotype groupings. ANOVA examined the 
relationship of genotype, statins, and HOMA-IR. Regression 
analysis was performed to analyze the relationship between 
BDNF genotype status and HOMA-IR, whereas controlling for 
variables we found to signifi cantly eff ect HOMA-IR. HOMA-IR 
was used as the dependent variable while the genotype-based 
groups and the variables aff ecting HOMA-IR (detailed in results) 
were used as the independent variables for each aim stated above. 
We then analyzed based on each diagnosis given the diff erences 
in pathogenesis and medication use for these two diseases. All 
analyses utilized the JMP 9.0 statistical program. A  p -value < 0.05 
with a 95% confi dence interval was considered signifi cant. 
 Results 
 Aft er excluding based on the criteria above (diagnosis of diabetes 
or current diabetes treatment), our fi nal sample size for data 
analysis was 252 (148 with a schizophrenia spectrum diagnosis 
and 104 with a bipolar diagnosis). See  Table  1 for demographic 
characteristics. Th e BDNF Val66Met genotypes were in Hardy 
Weinberg Equilibrium for the entire cohort as well as for each 
diagnosis spectrum (all  p > 0.26). Eight participants were unable 
to be genotyped. 
 Comparisons of all subject found a few signifi cant diff erences. 
Th e schizophrenia cohort had a higher percentage of male and 
African American subjects compared to the bipolar cohort 
( p   <  0.05 for both), there were more schizophrenia subjects 
receiving AAPs ( p = 0.02), diff erences in the percentage of subjects 
who were current smokers ( p = 0.01) and diff erences in lipid levels 
between the two cohorts (Total Cholesterol:  p = 0.003; HDL: 
 p = 0.01; LDL:  p = 0.02). See  Table  1 for percentage comparisons 
between the two groups. 
 Preliminary analysis found that in the combined sample, 
the Met allele carriers were older (46 vs. 43 years old,  p = 0.043), 
less likely to be African Americans (5% vs. 26%,  p = 0.005), and 
had higher AAP use (89% vs. 73%,  p = 0.010). Th ere were no 
signifi cant diff erences for the schizophrenia or bipolar groups 
based on genotype 
 No signifi cant relationship was found between the BDNF 66 
Met allele and HOMA-IR for the whole group ( p = 0.3). However 
when segregated by diagnosis, we found a signifi cant eff ect of the 
BDNF 66Met allele on HOMA-IR in the schizophrenia sample 
where subjects carrying the Met allele had higher HOMA-IRs ( p = 
0.046). No relationship was found for the bipolar group (analysis 
in  Table  2 ,  Figure  1 ). 
 Th ere were no eff ects of statin medications on BDNF 66Met allele 
carriers in the entire cohort ( p = 0.2). However, the schizophrenia 
subjects currently taking statin medications and carrying the Met 
allele had signifi cantly higher HOMA-IRs compared to all other 
schizophrenia subjects ( p = 0.016). No relationship was found in 
the bipolar cohort (analysis in  Table  2 ). 
 In addition to the previous analysis, a linear regression was 
performed for each dependent variable (e.g., BDNF and statin status) 
controlling for age, race, AAP use, BMI and metabolic syndrome. In 
the combined sample, there was a signifi cant interaction between 
BMI and BDNF 66Met carriers on HOMA-IR (f[1,1] = 3.90,  p = 
0.049), where those with this allele, had higher levels of insulin 
resistance and similar BMIs compared to the Val/Val genotype 
groups. Th is analysis yielded no signifi cant results for the bipolar 
sample. Within the schizophrenia subset, the eff ect of the BDNF 
66Met allele on HOMA-IR was signifi cant by itself (f[11,135] = 4.80, 
 p = 0.030) as well as 66Met’s interaction with BMI on HOMA-IR 
(f(1,1) = 9.04,  p = 0.0032). Finally, only the interaction between 
BMI and genotype was seen in the schizophrenia sample when the 
analysis was stratifi ed by statin use (f[1,1] = 6.26,  p = 0.037), where 
those with the 66Met allele receiving a statin also had higher levels 
of insulin resistance at comparable BMIs. 
 Discussion 
 For this study, we found a signifi cant relationship between BMI, 
the BDNF 66 Met allele and insulin resistance in a schizophrenia 
488 VOLUME 5 • ISSUE 6 WWW.CTSJOURNAL.COM
Burghardt et al. ■ BDNF and Insulin Resistance in the Schizophrenia and Bipolar Populations
population primarily treated with AAPs. Our study showed 
that BDNF pharmacogenetics may not be the same across 
diff erent populations prescribed AAPs or statins with the lack 
of a relationship seen in the combined and bipolar groups. Th is 
may suggest glucose regulation is more dependent on genetic 
factors like BDNF within schizophrenia. Of note, is that within 
our samples, the HOMA-IR values are substantially higher than 
general population studies, which is not surprising given the 
rising incidence of diabetes and metabolic syndrome. Studies in 
other populations have HOMA-IR averages of 1.8–2.9 whereas 
our average was much higher at 5.51 and 5.91 ( Table  1 ) for the 
schizophrenia and bipolar samples, respectively. 21,22 Contributing 
to the elevated HOMA-IR may be high AAP use (78% overall) with 
the majority being AAPs with strong metabolic side eff ect profi les. 
Although not statistically signifi cant, schizophrenia subjects on 
clozapine, olanzapine, risperidone, paliperidone or quetiapine 
(68%) had a mean HOMA-IR of 5.8 versus those on ziprasidone, 
aripiprazole or 1st generation antipsychotics with a HOMA-IR 
of 5.0 ( p = 0.25) which is consistent with the literature. 23 Poor 
diet and a lack of activity could also be contributors to these 
high HOMA-IR values. Furthermore, for the combined sample, 
80% had a HOMA-IR higher than a suggested threshold of 2.6 
for insulin resistance. 
 Our study contradicts previous reports showing no association 
between the BDNF Val66Met polymorphism and HOMA-IR in the 
diabetic population 6 as we found a signifi cant association between 
BMI, the BDNF 66Met allele and insulin resistance within our 
schizophrenia sample. Th us, the BDNF Val66Met variant which has 
been studied for its psychiatric and cognitive eff ects 8,24,25 may also 
impact insulin resistance risk within schizophrenia, but perhaps not 
Variable
Schizophrenia spectrum 
disorders ( n = 148)
Bipolar disorder 
( n = 104)
Combined sample 
( n = 252)
Age (years ± s.d) 44.8 ± 11.7 42.7 ± 12.0 43.9 ± 11.9
% Male * 66 35 53
% Caucasian/% African American * 61/30 84/11 71/22
% On Atypical Antipsychotics * 83 70 78
% On Clozapine or Olanzapine/% On Risperi-
done, Quetiapine, Iloperidone or Paliperidone * 
28/37 15/56 23/43
% On Statins 19 18 19
% Smoking * 49 32 42
% With ATP III/NCEP Metabolic Syndrome 30 26 29
BMI (kg/m 2 ± s.d.) 31.4 ± 7.15 32.1 ± 8.88 31.7 ± 7.9
Blood pressure (mmHg ± s.d.) 122/75 ± 16/12 124/73 ± 18/11 123/74 ± 17/11
Total cholesterol (mg/dL ± s.d.) * 176 ± 39.2 192 ± 44.7 182 ± 42.2
Triglycerides (mg/dL ± s.d.) 131 ± 89.3 138 ± 104 134 ± 95.7
High-density lipoprotein (mg/dL ± s.d) * 52.7 ± 16.3 58 ± 14.9 54.9 ± 15.9
Low-density lipoprotein (mg/dL ± s.d.) * 108 ± 30.6 118 ± 38.2 112 ± 34.3
Insulin (mU/L ± s.d.) 22.9 ± 15.2 24.2 ± 20.8 23.5 ± 17.7
Glucose (mg/dL ± s.d.) 96.1 ± 12.5 96.0 ± 12.0 96.0 ± 12.3
HbA1C% 5.63 5.55 5.60
HOMA-IR ± s.d. 5.51 ± 3.92 5.91 ± 5.46 5.68 ± 4.62






% With BDNF 66Met Allele 28 23 26
 *Indicates  p < 0.05 when comparing the Schizophrenia and Bipolar samples. 
 Table 1.  Analysis of demographic variables. 
Schizophrenia spectrum disorders Bipolar disorder Combined sample
Subject groups HOMA-IR ± s.d.  p -value HOMA-IR ± s.d.  p -value HOMA-IR ± s.d.  p -value
 BDNF 66ValVal Genotype 5.10 ± 0.400 0.046 6.04 ± 0.621 0.7 5.52 ± 0.352 0.3
 BDNF 66Met Allele Carriers 6.63 ± 0.642 5.47 ± 1.12 6.18 ± 0.594
 BDNF Val66 with or without Statins 
and  BDNF 66Met without Statins
5.30 ± 0.350 0.016 5.99 ± 0.553 0.5 5.60 ± 0.312 0.2
 BDNF 66Met Carriers and Currently 
Taking a Statin
8.45 ± 1.24 3.99 ± 2.74 7.15 ± 1.25
 Table 2.  Analysis of HOMA-IR based on BDNF Met carrier and Statin Status. 
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within other populations that uses AAPs. BMI and HOMA-IR are 
easily measureable clinical variables that may represent risk factors 
in schizophrenia, along with the BDNF Val66Met genotype to help 
predict greatest insulin resistance risk. Subjects may then be targeted 
for specifi c interventions related to insulin resistance to prevent 
the development of diabetes and its detrimental comorbidities 
and cost. Although the bipolar sample did not show a correlation 
with the BDNF 66Met variant, their high insulin resistance values 
suggest that they should be studied further in order to determine 
personalized approaches to diabetes risk. 
 Statin medication use within the general population is 
becoming more controversial. We hypothesized that in subjects 
with the BDNF 66Met allele, statin use may result in greater 
insulin resistance. Based on our analysis, we found a signifi cant 
relationship in schizophrenia patients taking statins and carrying 
the 66Met allele resulting in a HOMA-IR measure about 1.5× 
higher than those patients either with the Val allele taking statins 
or those regardless of BDNF genotype not taking statins ( Table  2 ). 
Also, the combination of the 66Met allele and statin use resulted 
in a HOMA-IR value more than 1.2 times higher than those 
patients carrying the 66Met allele alone. Th is was not seen in 
the bipolar population. Aft er controlling for age, race, AAP use, 
BMI and metabolic syndrome, these relationships remained 
( p = 0.0032) suggesting that at any given BMI, schizophrenia 
BDNF 66Met allele carriers receiving a statin medication have 
signifi cantly higher HOMA-IR values. Th e combined eff ect of 
statin use and the BDNF 66Met allele on HOMA-IR within this 
population could be a result of increased proteolytic cleavage 
(induced by statins) of the altered form of BDNF dictated by the 
Met variant whereas ValVal schizophrenia patients are unaff ected 
by this increased cleavage since they are not producing the altered 
form of the BDNF protein. 10,13 Again, with further validation 
future personalized medicine approachs in schizophrenia could 
be developed when treating hyperlipidemia. 
 Figure  1 depicts the diff ering HOMA-IR trends between 
the groups as more insulin resistance risk factors (e.g., BDNF 
Val66Met polymorphism and statins) are added together. 
Originally, we hypothesized that BDNF’s pharmacogenetic 
eff ects and statins would be the same on both populations. 
Th e diff erent trends could be a result of diff ering baseline 
characteristics between the groups (gender, AAP use, lipid 
levels, etc.) that could not be fully controlled during analysis, 
pathophysiologic processes of the diseases or diff erences in 
baseline diabetes risk. Also, it may be possible that the BDNF 
protein may not be a major contributor to insulin resistance in the 
bipolar population and thus, the hypothesis of increased BDNF 
cleavage we proposed for the schizophrenia population would 
not have the same eff ect. Finally, although the mechanism for 
statin-induced insulin resistance has not been fully elucidated, 
diff erences in transporter expression between schizophrenia 
and bipolar patients could be a future line of investigation into 
the diff erences seen within our study. 26,27 
 Figure 1.  Graph of Analysis of HOMA-IR based on BDNF Met carrier and Statin Status.  This fi gure depicts the analysis detailed in  Table  2 . The groups “BDNF Val/Val” and 
“BDNF 66Met Carriers” are from the primary analysis of this study looking at the pharmacogenetic effect of BDNF Val66Met on insulin resistance. The groups “BDNF Val/Val 
with or without statins and BDNF 66Met without Statins” and “BDNF 66Met Carriers and currently taking a Statin” are from the secondary analysis stratifying BDNF Val66Met 
status by current statin use. The fi gure depicts the differing effects seen in the bipolar and schizophrenia samples of adding these variables together on the insulin resistance 
measure of HOMA-IR. 
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 One major study limitation is that BDNF levels were not 
measured, however to date, the BDNF Val66Met has not been 
well correlated to BDNF levels. 28 Another limitation is use of a the 
HOMA-IR to assess insulin resistance, however, this measurement 
correlates well with more invasive measures of insulin resistance 
such as the frequently sampled IV glucose tolerance test. 29,30 Th e 
cross-sectional design of our study only gives us a snapshot of insulin 
resistance and needs replication in order to confi rm our results. 
Our study population was also not drug naïve and polypharmacy 
was fairly common in regards to overall number of medications, 
making it diffi  cult to confi rm the interaction of the BDNF gene, 
AAPs and statins within the mental illness. Our candidate gene 
drive study only looked at the BDNF Val66Met polymorphism 
because other BDNF polymorphisms have not been studied in 
insulin resistance in the literature. However, possible associations 
with other variants cannot be ruled out. Lastly, we did not control 
for multiple comparisons, however, our most signifi cant result in 
the schizophrenia population would sustain the more stringent 
multiple testing signifi cance level of 0.01. 
 Conclusion 
 Overall our cross-sectional study of schizophrenia and bipolar 
patients receiving antipsychotic treatment showed that in 
schizophrenia subjects, insulin resistance is associated with the 
BDNF 66Met allele, statin medications and BMI. No association 
was found for the bipolar disorder subjects. Although further 
validation is needed, the BDNF Val66Met variant, thought 
to be promising in predicting insulin resistance and glucose 
dysregulation, may play a role in predicting risk of developing 
insulin resistance and subsequently diabetes from AAP use in 
the schizophrenia population. Th is work helps to target genes of 
interest which can be followed up in future investigations, focusing 
on personalized medicine for those with schizophrenia. 
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